Dutasteride significantly improves quality of life measures in patients with enlarged prostate

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 2, 2008, Pages 129-133

  O'Leary, M P ^a   Roehrborn, C G ^b   Black, L ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; BENIGN PROSTATIC HYPERPLASIA INTERFERENCE WITH ACTIVITIES; BENIGN PROSTATIC HYPERPLASIA LIFESTYLE ADAPTATIONS; BENIGN PROSTATIC HYPERPLASIA PSYCHOLOGICAL WELLBEING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM PROBLEM INDEX;

ADAPTATION, PSYCHOLOGICAL; AGED; AZASTEROIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 43549124856     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500990     Document Type: Article

References (17)

1. Roehrborn CG, Marks L, Harkaway R. Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 2006; 9: 30-34.
2. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarette R et al. Benign prostatic hyperplasia: A progressive disease of aging men. Urology 2003; 61: 267-273.
3. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-284.
4. Arocho R, McMillan CA, Sutton-Wallance P. Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7: 121-126.
5. Spencer S, Calverly PM, Sherwood Burge P, Jones PW, for the ISOLDE Study Group. Inhaled steroids in obstructive lung disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128.
6. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
7. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA, on behalf of the Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic ehyperplasia: A primary care study. Clin Ther 1997; 19: 243-258.
8. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-563.
9. Roehrborn CG, Boyle P, Nickel JC, Hoefner K. Andriole G, on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.
10. Clark RV, Hermann,DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179.
11. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557.
12. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 (4 Suppl): AS145-AS155.
13. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-1445.
14. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/ lower urinary tract symptoms: An overview for the practising clinician. BJU Int 2004; 94: 738-744.
15. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: Results of 4-year studies. BJU Int 2005; 96: 572-577.
16. Roehrborn CG, O'Leary M, Black L. Measurement of the effect of dutasteride on worry and embarrassment associated with lower urinary tract symptoms in men with BPH: Use of a novel instrument [poster]. Presented at the European Association of Urology 2005 Meeting, 19 March 2005 Istanbul, Turkey.
17. O'Leary MP, Roehrborn C, Andriole G, Nikel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003; 92: 262-266.